Despite the realization that half of patients with uveal melanoma will ultimately develop metastatic disease, questions remain regarding the utility of routine surveillance. In 2011, a literature review of 31 articles failed to demonstrate convincing evidence of a survival advantage from routine surveillance.1 However, these studies were conducted in the context of traditional chemotherapy regimens, none of which demonstrated adequate response rates for uveal melanoma. A phase 2 trial of selumetinib conducted between 2010 and 2013 yielded improved response rates and progression-free survival (despite no improvement in overall survival) compared with chemotherapy.2 These landmark findings shed some hope on the dismal landscape of metastatic uveal melanoma and have thus reignited the potential benefit of routine surveillance and early detection of disease.
Francis JH. Is Surveillance of Uveal Melanoma Just a Screen?. JAMA Ophthalmol. 2016;134(2):180-181. doi:10.1001/jamaophthalmol.2015.4817